



Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

May 19, 2026

Iambic is a CNBC Disruptor 50 for the second year in a row

San Diego, CA – May 19, 2026 – [Iambic](#) is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recognize the most innovative and fast-growing private companies reshaping the economy. Nominees go through a rigorous vetting process based on scalability, customer growth, and use of breakthrough technology.

“Iambic is proving that better technology leads to better medicines, and this recognition as a repeat Disruptor reflects the company’s execution, momentum, and vision,” said Tom Miller, PhD, Co-founder and CEO of Iambic. “Drug discovery will be transformed by molecular superintelligence — the convergence of advanced AI with automated, high-throughput experimentation. At Iambic, we are building that future today with a discovery engine designed to deliver new medicines with greater speed, differentiation, and repeatable success.”

Pictured: Co-Founders and CEO Tom Miller, PhD (right) & CTO Fred Manby, PhD

Iambic’s Winning Year

The past 12 months were significant for Iambic: the company announced major partnerships with Takeda, Revolution Medicines, Jazz Pharmaceuticals, and Lambda AI, in addition to Lundbeck and NVIDIA. These deals represent a mix of discovery, technology, and clinical development. Iambic’s collaboration with Takeda is one of the largest AI-driven drug discovery deals ever, worth up to \$1.7 billion, and includes access to Iambic technology and discovery programs for targets related to cancer, gastrointestinal and inflammatory disease.

In 2025, Iambic broke new ground as an AI-native drug discovery company, announcing clinical data for the activity and safety of a platform-discovered asset that was delivered to clinic in just two years – about one-third industry standard time. IAM1363 for HER2-driven cancers showed anti-tumor activity in heavily pretreated patients across multiple disease types in data revealed at ESMO 2025. Also in 2025, Iambic released Enchant v2, its breakthrough multimodal transformer model with exceptional predictive power in the most data-constrained settings. NeuralPLexer, Iambic’s AI tool for protein-ligand structure prediction, continued to garner interest – Takeda and Revolution Medicines are users.

Enchant and NeuralPLexer are foundational to Iambic’s AI-driven platform, used to rapidly advance an internal pipeline of potential category-defining medicines. This pipeline includes CDK2/4, a potential first-in-class small molecule inhibitor drug candidate for various cancers, and KIF18A, a potential best-in-class allosteric inhibitor drug candidate for solid tumors. Both programs continue to progress through IND-enabling studies.

Iambic was co-founded by award-winning chemistry professors and collaborators, Tom Miller, PhD, CEO and Fred Manby, PhD, CTO in 2020. In just six years the company has raised over \$350 million, retained over 140 employees globally, and established its headquarters and labs in San Diego with additional offices in the UK and Boston.

About Iambic

Iambic is proving that better technology leads to better medicines. By pioneering molecular superintelligence — integrating proprietary AI with automated, high-throughput experimentation — we are transforming how medicines are made. Our platform was validated by the discovery of a novel drug candidate advanced to clinic in about one-third industry-standard time, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building the engine that will power the future of medicine. | [Iambic.ai](#)

Media Contact:

Amanda Guisbond
Head of Communications, Iambic
media@iambic.ai